Compare SRPT & HTGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRPT | HTGC |
|---|---|---|
| Founded | 1980 | 2003 |
| Country | United States | United States |
| Employees | N/A | 50 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | 2000 | N/A |
| Metric | SRPT | HTGC |
|---|---|---|
| Price | $21.06 | $16.01 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 29 | 7 |
| Target Price | ★ $25.85 | $18.86 |
| AVG Volume (30 Days) | ★ 2.3M | 1.7M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 12.13% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,198,237,000.00 | N/A |
| Revenue This Year | N/A | $11.18 |
| Revenue Next Year | N/A | $5.24 |
| P/E Ratio | ★ N/A | $8.61 |
| Revenue Growth | ★ 15.58 | N/A |
| 52 Week Low | $10.42 | $13.70 |
| 52 Week High | $64.80 | $19.67 |
| Indicator | SRPT | HTGC |
|---|---|---|
| Relative Strength Index (RSI) | 52.71 | 61.95 |
| Support Level | $20.61 | $13.77 |
| Resistance Level | $22.69 | $16.08 |
| Average True Range (ATR) | 0.90 | 0.36 |
| MACD | -0.18 | 0.03 |
| Stochastic Oscillator | 65.94 | 94.14 |
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Hercules Capital Inc is a specialty finance company focused on providing senior secured loans to high-growth, venture capital-backed, and institutional-backed companies in a variety of technology and life sciences industries. The company's primary business objectives are to increase its net income, net investment income, and net asset value (NAV) through its investments mainly in structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. It finances companies belonging to computer software and hardware, networking systems, semiconductors, medical devices, bio-pharmaceutical, and other related sectors.